A highly sensitive fluorescent probe that quantifies transthyretin in human plasma as an early diagnostic tool of Alzheimer's disease

2019 ◽  
Vol 55 (70) ◽  
pp. 10424-10427 ◽  
Author(s):  
Hye Rim Lim ◽  
Seo Yun Kim ◽  
Eun Hee Jeon ◽  
Yun Lan Kim ◽  
Yu Mi Shin ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Human Plasma ◽  
Fluorescent Probe ◽  
Diagnostic Tool ◽  
Fluorescent Assay ◽  
Highly Sensitive ◽  
Early Diagnostic

A robust and simple fluorescent assay for the quantification of TTR in human plasma was developed by utilizing an indole-based fluorophore.

scholarly journals The Role of Salivary Biomarkers in the Early Diagnosis of Alzheimer’s Disease and Parkinson’s Disease

Diagnostics ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. 371
Author(s):  
Patrycja Pawlik ◽  
Katarzyna Błochowiak
Keyword(s):  
Alzheimer’S Disease ◽  
Parkinson’S Disease ◽  
Alzheimer's Disease ◽  
Parkinson's Disease ◽  
Early Diagnosis ◽  
Neurodegenerative Diseases ◽  
Diagnostic Tool ◽  
Clinical Symptoms ◽  
Early Screening ◽  
Salivary Biomarkers

Many neurodegenerative diseases present with progressive neuronal degeneration, which can lead to cognitive and motor impairment. Early screening and diagnosis of neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD) are necessary to begin treatment before the onset of clinical symptoms and slow down the progression of the disease. Biomarkers have shown great potential as a diagnostic tool in the early diagnosis of many diseases, including AD and PD. However, screening for these biomarkers usually includes invasive, complex and expensive methods such as cerebrospinal fluid (CSF) sampling through a lumbar puncture. Researchers are continuously seeking to find a simpler and more reliable diagnostic tool that would be less invasive than CSF sampling. Saliva has been studied as a potential biological fluid that could be used in the diagnosis and early screening of neurodegenerative diseases. This review aims to provide an insight into the current literature concerning salivary biomarkers used in the diagnosis of AD and PD. The most commonly studied salivary biomarkers in AD are β-amyloid1-42/1-40 and TAU protein, as well as α-synuclein and protein deglycase (DJ-1) in PD. Studies continue to be conducted on this subject and researchers are attempting to find correlations between specific biomarkers and early clinical symptoms, which could be key in creating new treatments for patients before the onset of symptoms.

P2-176: Are cortical sources of auditory oddball event-related potentials an early diagnostic marker of Alzheimer's disease?

2015 ◽  
Vol 11 (7S_Part_12) ◽  
pp. P559-P559
Author(s):  
Claudio Babiloni ◽  
Claudio Del Percio ◽  
Nicola Marzano ◽  
Susanna Cordone ◽  
Giuseppe Noce ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Diagnostic Marker ◽  
Event Related Potentials ◽  
Auditory Oddball ◽  
Cortical Sources ◽  
Related Potentials ◽  
Early Diagnostic

scholarly journals Clinically accurate diagnosis of Alzheimer’s disease via multiplexed sensing of core biomarkers in human plasma

2020 ◽  
Vol 11 (1) ◽  
Author(s):  
Kayoung Kim ◽  
Min-Ji Kim ◽  
Da Won Kim ◽  
Su Yeong Kim ◽  
Steve Park ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Human Plasma ◽  
Sensor Array ◽  
Neurodegenerative Disorder ◽  
Limit Of Detection ◽  
Average Accuracy ◽  
Severity Of The Disease ◽  
High Degree ◽  
T Tau

AbstractAlzheimer’s disease (AD) is the most prevalent neurodegenerative disorder, affecting one in ten people aged over 65 years. Despite the severity of the disease, early diagnosis of AD is still challenging due to the low accuracy or high cost of neuropsychological tests and neuroimaging. Here we report clinically accurate and ultrasensitive detection of multiple AD core biomarkers (t-tau, p-tau181, Aβ42, and Aβ40) in human plasma using densely aligned carbon nanotubes (CNTs). The closely packed and unidirectionally aligned CNT sensor array exhibits high precision, sensitivity, and accuracy, evidenced by a low coefficient of variation (<6%), a femtomolar-level limit of detection, and a high degree of recovery (>93.0%). By measuring the levels of t-tau/Aβ42, p-tau181/Aβ42, and Aβ42/Aβ40 in clinical blood samples, the sensor array successfully discriminates the clinically diagnosed AD patients from healthy controls with an average sensitivity of 90.0%, a selectivity of 90.0%, and an average accuracy of 88.6%.

scholarly journals Automated MRI volumetry as a diagnostic tool for Alzheimer's disease: Validation of icobrain dm

2020 ◽  
Vol 26 ◽  
pp. 102243 ◽  
Author(s):  
Hanne Struyfs ◽  
Diana Maria Sima ◽  
Melissa Wittens ◽  
Annemie Ribbens ◽  
Nuno Pedrosa de Barros ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Diagnostic Tool ◽  
Mri Volumetry
Sign in / Sign up

Export Citation Format

Share Document